`
`Patent Owner's Mandatory Notices Patent Owner's Mandatory Notices
`
`
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`AGILA SPECIALTIES INC. and MYLAN LABORATORIES LIMITED, AGILA SPECIALTIES INC. and MYLAN LABORATORIES LIMITED,
`
`Petitioners Petitioners
`
`
`
`v. v.
`
`
`CEPHALON, INC. CEPHALON, INC.
`
`Patent Owner Patent Owner
`
`
`Case IPR2016-00026 Case IPR2016-00026
`
`Patent No. 8,791,270 Patent No. 8,791 270
`
`
`PATENT OWNER'S UPDATED MANDATORY NOTICES PATENT OWNER'S UPDATED MANDATORY NOTICES
`
`PURSUANT TO 37 C.F.R. § 42.8 PURSUANT TO 37 C.F.R. § 42.8
`
`
`Mail Stop "PATENT BOARD" Mail Stop "PATENT BOARD"
`
`Patent Trial and Appeal Board Patent Trial and Appeal Board
`
`United States Patent and Trademark Office United States Patent and Trademark Office
`
`P.O. Box 1450 P.O. Box 1450
`
`Alexandria, VA 22313-1450 Alexandria, VA 22313-1450
`
`
`
`
`IPR2016-00026 IPR2016-00026
`
`Patent Owner's Mandatory Notices Patent Owner's Mandatory Notices
`
`
`
`Pursuant to 37 C.F.R. § 42.8(a)(3), (b)(2), (b)(3), and (b)(4), Patent Owner, Pursuant to 37 C.F.R. § 42.8(a)(3), (b)(2), (b)(3), and (b)(4), Patent Owner,
`
`
`
`Cephalon, Inc. ("Cephalon"), hereby submits the following updated mandatory Cephalon, Inc. ("Cephalon"), hereby submits the following updated mandatory
`
`
`
`notices. notices.
`
`I. (cid:9)
`I. (cid:9)
`
`RELATED MATTERS (37 C.F.R. § 42.8(b)(2))
`RELATED MATTERS (37 C.F.R. § 42.8(b)(2))
`
`
`
`A. (cid:9)A. (cid:9)
`
`
`
`Judicial Matters Judicial Matters
`
`
`
`U.S. Patent No. 8,791,270 ("'270 Patent") has been or is currently at issue in U.S. Patent No. 8,791,270 ("'270 Patent") has been or is currently at issue in
`
`
`
`the following district court litigation: the following district court litigation:
`
`
`
`• Cephalon, Inc. v. Apotex, Inc., No. 1:15-cv-00404-GMS (D. Del.); • Cephalon, Inc. v. Apotex, Inc., No. 1:15-cv-00404-GMS (D. Del.);
`
`
`
`• Cephalon, Inc. v. Panacea Biotec, Ltd., No. 1:15-cv-00735-GMS (D. • Cephalon, Inc. v. Panacea Biotec, Ltd., No. 1:15-cv-00735-GMS (D.
`
`Del.);
`Del.);
`
`
`
`• Cephalon, Inc. v. Nang Kuang Pharm. Co., Ltd., 1:14-cv-01117-GMS • Cephalon, Inc. v. Nang Kuang Pharm. Co., Ltd.,1:14-cv-01117-GMS
`
`
`
`(D. Del.); and (D. Del.); and
`
`
`
`• Cephalon, Inc. v. Nang Kuang Pharm. Co., Ltd., No. 1:14-cv-05180-• Cephalon, Inc. v. Nang Kuang Pharm. Co., Ltd., No. 1:14-cv-05180-
`
`
`
`KAM-RER (E.D.N.Y.). KAM-RER (E.D.N.Y.).
`
`Additionally, the following Delaware district court litigations involving the
`Additionally, the following Delaware district court litigations involving the
`
`
`
`'270 Patent (and/or related patents) were consolidated into In re Bendamustine '270 Patent (and/or related patents) were consolidated into In re Bendamustine
`
`
`
`Consol. Cases, No. 1:13-cv-02046-GMS (D. Del.): Consol. Cases, No. 1:13-cv-02046-GMS (D. Del.):
`
`
`
`• Cephalon Inc. v. Eagle Pharms. Inc., No. 1:13-cv-01738-GMS (D. • Cephalon Inc. v. Eagle Pharms. Inc., No. 1:13-cv-01738-GMS (D.
`
`Del.);
`Del.);
`
`
`
`1 1
`
`
`
`
`IPR2016-00026 IPR2016-00026
`
`Patent Owner's Mandatory Notices Patent Owner's Mandatory Notices
`
`
`
`• Cephalon Inc. v. Hetero Labs Ltd., 1:13-cv-02046-GMS (D. Del.); • Cephalon Inc. v. Hetero Labs Ltd., 1:13-cv-02046-GMS (D. Del.);
`
`
`
`• Cephalon Inc. v. Agila Specialties Inc., 1:13-cv-02080-GMS (D. • Cephalon Inc. v. Agila Specialties Inc., 1:13-cv-02080-GMS (D.
`
`
`
`Del.); Del.);
`
`
`
`• Cephalon Inc. v. InnoPharma Inc., No. 1:13-cv-02081-GMS (D. • Cephalon Inc. v. InnoPharma Inc., No. 1:13-cv-02081-GMS (D.
`
`
`
`Del.); Del.);
`
`
`
`• Cephalon, Inc. v. Dr. Reddy's Labs., Ltd., No. 1:13-cv-02082-GMS • Cephalon, Inc. v. Dr. Reddy's Labs., Ltd., No. 1:13-cv-02082-GMS
`
`
`
`(D. Del.); (D. Del.);
`
`
`
`• Cephalon, Inc. v. Glenmark Pharms. Ltd., No. 1:13-cv-02093-GMS • Cephalon, Inc. v. Glenmark Pharms. Ltd., No. 1:13-cv-02093-GMS
`
`(D. Del.);
`(D. Del.);
`
`
`
`• Cephalon Inc. v. Hospira Inc., No. 1:13-cv-02094-GMS (D. Del.); • Cephalon Inc. v. Hospira Inc., No. 1:13-cv-02094-GMS (D. Del.);
`
`
`
`• Cephalon, Inc. v. Accord Healthcare, Inc., 1:13-cv-02095-GMS (D. • Cephalon, Inc. v. Accord Healthcare, Inc., 1:13-cv-02095-GMS (D.
`
`
`
`Del.); Del.);
`
`
`
`• Cephalon, Inc. v. Sun Pharma Global FZE, No. 1:13-cv-02096-GMS • Cephalon, Inc. v. Sun Pharma Global FZE, No. 1:13-cv-02096-GMS
`
`
`
`(D. Del.); (D. Del.);
`
`
`
`• Cephalon Inc. v. Sandoz Inc., No. 1:13-cv-02104-GMS (D. Del.); • Cephalon Inc. v. Sandoz Inc., No. 1:13-cv-02104-GMS (D. Del.);
`
`
`
`• Cephalon, Inc. v. Actavis LLC f/k/a Actavis Inc., 1:14-cv-00122-GMS • Cephalon, Inc. v. Actavis LLC f/k/a Actavis Inc., 1:14-cv-00122-GMS
`
`
`
`(D. Del.); (D. Del.);
`
`
`
`• Cephalon, Inc. v. Sun Pharma Global FZE, No. 1:14-cv-00333-GMS • Cephalon, Inc. v. Sun Pharma Global FZE, No. 1:14-cv-00333-GMS
`
`
`
`(D. Del.); (D. Del.);
`
`
`
`2 2
`
`
`
`
`IPR2016-00026 IPR2016-00026
`
`Patent Owner's Mandatory Notices Patent Owner's Mandatory Notices
`
`
`
`• Cephalon, Inc. v. Dr. Reddy's Labs., Ltd., No. 1:14- cv-00334-GMS • Cephalon, Inc. v. Dr. Reddy's Labs., Ltd., No. 1:14- cv-00334-GMS
`
`
`
`(D. Del.); (D. Del.);
`
`• Cephalon, Inc. v. Emcure Pharms., Ltd., No. 1:14-cv-00335-GMS (D.
`• Cephalon, Inc. v. Emcure Pharms., Ltd., No. 1:14-cv-00335-GMS (D.
`
`
`
`Del.); Del.);
`
`• Cephalon, Inc. v. Pharmasci. Inc., 1:14-cv-00568-GMS (D. Del.);
`• Cephalon, Inc. v. Pharmasci. Inc., 1:14-cv-00568-GMS (D. Del.);
`
`
`
`• Cephalon Inc. v. InnoPharma Inc., No. 1:14-cv-00590-GMS (D. • Cephalon Inc. v. InnoPharma Inc., No. 1:14-cv-00590-GMS (D.
`
`
`
`Del.); Del.);
`
`
`
`• Cephalon, Inc. v. Breckenridge Pharm., Inc.,1:14-cv-00671-GMS (D. • Cephalon, Inc. v. Breckenridge Pharm., Inc.,1:14-cv-00671-GMS (D.
`
`
`
`Del.); Del.);
`
`
`
`• Cephalon Inc. v. Eagle Pharms. Inc., No. 1:14-cv-01042-GMS (D. • Cephalon Inc. v. Eagle Pharms. Inc., No. 1:14-cv-01042-GMS (D.
`
`
`
`Del.); Del.);
`
`
`
`• Cephalon, Inc. v. Eurohealth (cid:9)• Cephalon, Inc. v. Eurohealth (cid:9)
`
`
`
`Sarl, 1:14-cv-01045-GMS (D. Sarl, 1:14-cv-01045-GMS (D.
`
`
`
`Del.); Del.);
`
`
`
`• Cephalon, Inc. v. Sagent Pharms, Inc., 1:14-cv-01116-GMS (D. Del.); • Cephalon, Inc. v. Sagent Pharms, Inc., 1:14-cv-01116-GMS (D. Del.);
`
`
`
`• Cephalon, Inc. v. Agila Specialties, Inc., No. 1:14-cv-01237-GMS (D. • Cephalon, Inc. v. Agila Specialties, Inc., No. 1:14-cv-01237-GMS (D.
`
`
`
`Del.); Del.);
`
`
`
`• Cephalon Inc. v. InnoPharma Inc., No. 1:14-cv-01238-GMS (D. • Cephalon Inc. v. InnoPharma Inc., No. 1:14-cv-01238-GMS (D.
`
`
`
`Del.); Del.);
`
`
`
`• Cephalon Inc. v. Sandoz Inc., 1:14-cv-01239-GMS (D. Del.); • Cephalon Inc. v. Sandoz Inc., 1:14-cv-01239-GMS (D. Del.);
`
`3
`3
`
`
`
`
`IPR2016-00026 IPR2016-00026
`
`Patent Owner's Mandatory Notices Patent Owner's Mandatory Notices
`
`
`
`• Cephalon, Inc. v. Dr. Reddy's Labs., Ltd., No. 1:14-cv-01241-GMS • Cephalon, Inc. v. Dr. Reddy's Labs., Ltd., No. 1:14-cv-01241-GMS
`
`
`
`(D. Del.); (D. Del.);
`
`
`
`• Cephalon Inc. v. Hospira Inc., No. 1:14-cv-01242-GMS (D. Del.); • Cephalon Inc. v. Hospira Inc., No. 1:14-cv-01242-GMS (D. Del.);
`
`
`
`• Cephalon, Inc. v. Sun Pharma Global FZE, No. 1:14-cv-01243-GMS • Cephalon, Inc. v. Sun Pharma Global FZE, No. 1:14-cv-01243-GMS
`
`
`
`(D. Del.); (D. Del.);
`
`
`
`• Cephalon, Inc. v. Wockhardt Bio Ltd., 1:14-cv-01332-GMS (D. Del.); • Cephalon, Inc. v. Wockhardt Bio Ltd., 1:14-cv-01332-GMS (D. Del.);
`
`
`
`• Cephalon Inc. v. Sandoz Inc., No. 1:15-cv-00178-GMS (D. Del.); and • Cephalon Inc. v. Sandoz Inc., No. 1:15-cv-00178-GMS (D. Del.); and
`
`
`
`• Cephalon, Inc. v. Dr. Reddy's Labs., Ltd., No. 15-cv-00179-GMS (D. • Cephalon, Inc. v. Dr. Reddy's Labs., Ltd., No. 15-cv-00179-GMS (D.
`
`
`
`Del.). Del.).
`
`
`
`B. Administrative B. Administrative
`
`The '270 Patent is the subject of a petition for Inter Partes Review in
`The '270 Patent is the subject of a petition for Inter Partes Review in
`
`
`
`IPR2016-00098. The Board has not yet decided whether to institute review on that IPR2016-00098. The Board has not yet decided whether to institute review on that
`
`petition.
`petition.
`
`The '270 Patent claims priority to U.S. Patent No. 8,436,190, which was at
`The '270 Patent claims priority to U.S. Patent No. 8,436,190, which was at
`
`
`
`issue in IPR2015-00503, now settled. issue in IPR2015-00503, now settled.
`
`The '270 Patent also claims priority to U.S. Patent No. 8,461,350 and U.S.
`The '270 Patent also claims priority to U.S. Patent No. 8,461,350 and U.S.
`
`
`
`Provisional Patent Application No. 60/644,354. U.S. Patent Nos. 8,895,756, Provisional Patent Application No. 60/644,354. U.S. Patent Nos. 8,895,756,
`
`
`
`8,436,190 and 8,609,863 also claim priority to U.S. Provisional Patent Application 8,436,190 and 8,609,863 also claim priority to U.S. Provisional Patent Application
`
`
`
`No. 60/644,354. No. 60/644,354.
`
`4
`4
`
`
`
`
`IPR2016-00026 IPR2016-00026
`
`Patent Owner's Mandatory Notices Patent Owner's Mandatory Notices
`
`
`
`U.S. Patent No. 8,895,756 is the subject of a petition for Inter Partes Review U.S. Patent No. 8,895,756 is the subject of a petition for Inter Partes Review
`
`
`
`in IPR2016-00111. The Board has not yet decided whether to institute review on in IPR2016-00111. The Board has not yet decided whether to institute review on
`
`
`
`that petition. that petition.
`
`
`
`Pending U.S. Patent Application No. 14/845,564 claims the benefit of the Pending U.S. Patent Application No. 14/845,564 claims the benefit of the
`
`
`
`'270 Patent. '270 Patent.
`
`
`
`II. (cid:9)II. (cid:9)
`
`
`
`LEAD AND BACKUP COUNSEL (37 C.F.R. § 42.8(b)(3)) LEAD AND BACKUP COUNSEL (37 C.F.R. § 42.8(b)(3))
`
`
`
`LEAD COUNSEL LEAD COUNSEL
`
`
`
`BACK-UP COUNSEL BACK-UP COUNSEL
`
`
`
`Soumitra (Sam) Deka Soumitra (Sam) Deka
`
`
`
`Aaron Stiefel Aaron Stiefel
`
`
`
`(Reg. No. 70,252) (Reg. No. 70,252)
`
`
`
`(Pro Hac Vice pending) (Pro Hac Vice pending)
`
`
`
`KAYE SCHOLER LLP KAYE SCHOLER LLP
`
`
`
`KAYE SCHOLER LLP KAYE SCHOLER LLP
`
`
`
`Two Palo Alto Square Two Palo Alto Square
`
`
`
`250 West 55th Street 250 West 55th Street
`
`
`
`3000 El Camino Real, Suite 400 3000 El Camino Real, Suite 400
`
`
`
`New York, NY 10019-9710 New York, NY 10019-9710
`
`
`
`Palo Alto, CA 94306 Palo Alto, CA 94306
`
`
`
`Tel: (212) 836-8000 Tel: (212) 836-8000
`
`
`
`Tel: (212) 836-8000 Tel: (212) 836-8000
`
`
`
`Fax: (212) 836-8689 Fax: (212) 836-8689
`
`
`
`Fax: (212) 836-8689 Fax: (212) 836-8689
`
`
`
`aaron. stiefel@kayescholer. corn aaron.stiefel@kayescholer.corn
`
`
`
`soumitra.deka@kayescholer.com soumitra.deka@kayescholer.com
`
`
`
`5 5
`
`
`
`IPR2016-00026
`IPR2016-00026
`
`Patent Owner's Mandatory Notices Patent Owner's Mandatory Notices
`
`
`
`III. SERVICE INFORMATION (37 C.F.R. § 42.8(b)(4)) III. SERVICE INFORMATION (37 C.F.R. § 42.8(b)(4))
`
`
`
`Please direct all correspondence to counsel using the contact infoiniation Please direct all correspondence to counsel using the contact information
`
`
`
`above. Petitioner consents to service by electronic mail at above. Petitioner consents to service by electronic mail at
`
`
`
`soumitra.deka@kayescholer.com and aaron.stiefel@kayescholer.corn. soumitra.deka@kayescholer.com and aaron.stiefel@kayescholer.corn.
`
`
`
`Dated: January 19, 2016 Dated: January 19, 2016
`
`
`Respectfully Submitted, Respectfully Submitted,
`
`KAYE SCHOLER LLP KAYE SCHOLER LLP
`
`/s/ Soumitra Deka
`/s/ Soumitra Deka
`
`
`Soumitra (Sam) Deka Soumitra (Sam) Deka
`
`(Reg. No. 70,252) (Reg. No. 70,252)
`
`Two Palo Alto Square Two Palo Alto Square
`
`3000 El Camino Real, Suite 400 3000 El Camino Real, Suite 400
`
`Palo Alto, CA 94306 Palo Alto, CA 94306
`
`Tel: (212) 836-8000 Tel: (212) 836-8000
`
`Fax: (212) 836-8689 Fax: (212) 836-8689
`
`
`
`Attorneys for Patent Owner Attorneys for Patent Owner
`
`6
`6
`
`
`
`
`IPR2016-00026 IPR2016-00026
`
`Patent Owner's Mandatory Notices Patent Owner's Mandatory Notices
`
`CERTIFICATE OF SERVICE
`CERTIFICATE OF SERVICE
`
`
`
`The undersigned hereby certifies that a copy of the foregoing document, The undersigned hereby certifies that a copy of the foregoing document,
`
`
`
`PATENT OWNER'S UPDATED MANDATORY NOTICES PURSUANT TO PATENT OWNER'S UPDATED MANDATORY NOTICES PURSUANT TO
`
`
`
`37 C.F.R. § 42.8, was served via electronic mail on January 19, 2016 to the 37 C.F.R. § 42.8, was served via electronic mail on January 19, 2016 to the
`
`
`
`following counsel of record for the Petitioners: following counsel of record for the Petitioners:
`
`
`
`Steven W. Paunelee Steven W. Pannelee
`
`
`
`sparmelee@wsgr.corn sparmelee@wsgr.corn
`
`
`
`WILSON SONSINI GOODRICH & ROSATI WILSON SONSINI GOODRICH & ROSATI
`
`
`
`Michael T. Rosato Michael T. Rosato
`
`
`
`mrosato@wsgr.com mrosato@wsgr.com
`
`
`
`WILSON SONSINI GOODRICH & ROSATI WILSON SONSINI GOODRICH & ROSATI
`
`
`
`Nicole Stafford Nicole Stafford
`
`
`
`nstafford@wsgr.cona nstafford@wsgr.corn
`
`
`
`WILSON SONSINI GOODRICH & ROSATI WILSON SONSINI GOODRICH & ROSATI
`
`
`
`Dated: January 19, 2016 Dated: January 19, 2016
`
`
`/s/ Soumitra Deka /s/ Soumitra Deka
`
`Soumitra (Sam) Deka Soumitra (Sam) Deka
`
`(Reg. No. 70,252) (Reg. No. 70,252)
`
`KAYE SCHOLER LLP KAYE SCHOLER LLP
`
`
`
`7 7